Cite

HARVARD Citation

    Yang, J. et al. (2020). Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study. European journal of cancer. pp. 182-192. [Online]. 
  
Back to record